EU antitrust charge for Servier, Teva, others over generics
BRUSSELS, July 30
BRUSSELS, July 30 (Reuters) - EU antitrust regulators charged French drugmaker Servier, Israel's Teva and four other firms on Monday with blocking the entry of generic perindopril medicine to market, its second major case against a key element of business in the pharmaceutical industry.
"At this stage, the (European) Commission takes the view that the patent settlement agreements concluded by Servier with Niche/Unichem, Matrix (today Mylan Laboratories Limited), Teva, Krka and Lupin, as well as Servier's acquisition of key competing technologies were aimed at delaying or preventing the market entry of cheap generic versions of perindopril, in violation of EU antitrust rules," the EU watchdog said in a statement.
- U.S. nurse quarantined over Ebola criticizes her treatment |
- U.S. diplomat travels to West Africa as Ebola quarantine moves take hold |
- Iraqi security forces and Kurds gain ground against Islamic State
- Washington state teen shooter's family living in 'nightmare'
- Suspect in two California deputy deaths charged with murder, carjacking